TR200200440T2 - ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler - Google Patents
ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemlerInfo
- Publication number
- TR200200440T2 TR200200440T2 TR2002/00440T TR200200440T TR200200440T2 TR 200200440 T2 TR200200440 T2 TR 200200440T2 TR 2002/00440 T TR2002/00440 T TR 2002/00440T TR 200200440 T TR200200440 T TR 200200440T TR 200200440 T2 TR200200440 T2 TR 200200440T2
- Authority
- TR
- Turkey
- Prior art keywords
- abc1
- compositions
- methods
- increase
- cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 title 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title 1
- 101000800403 Arabidopsis thaliana UPF0051 protein ABCI8, chloroplastic Proteins 0.000 title 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 abstract 8
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 abstract 8
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
Bu bulus, yeni ABC1 polipeptidleri ve bunlari kodlayan nükleik asit molekülleri, ayrica, ABC1 polinükleotidlerini ihtiva eden rekombinant vektörler, konak hücreler ve terkipler, ve ABC1 polipeptidlerini meydana getirmeye mahsus yöntemlerle ilgilidir.Bu bulus ayrica,ABC1 polipeptidlerine spesifik olarak baglanan antikorlar,kolesterolün disa akimini artirmak için yöntemler yani sira ABC1 in ekspresyonunu ve aktivitesini artirmaya mahsus yöntemler,ABC1 in ekspresyonun modüle eden bilesikleri tehshis etmek için yöntemler ve bir memelide, ABC1 polipeptidleri ve polinükleotidlerinin nisbi seviyesini belirlemek için yöntemlerle ilgilidir. Bu bulus ayrica, bilesiklerin ABC1 ekspresyonunu modüle etmek aktivitesini belirlemek için kitler ve terkipler yani sira, bir bilesigin, kolesterolün ABC1 e bagimli disa akimini ayarlayip ayarlamadigini belirlemek için uygun kitler ve terkipler de saglar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200440T2 true TR200200440T2 (tr) | 2002-09-23 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00441T TR200200441T2 (tr) | 1999-06-18 | 2000-06-16 | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. |
| TR2002/00440T TR200200440T2 (tr) | 1999-06-18 | 2000-06-16 | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00441T TR200200441T2 (tr) | 1999-06-18 | 2000-06-16 | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1218515B1 (tr) |
| JP (4) | JP2003506097A (tr) |
| KR (2) | KR100476519B1 (tr) |
| CN (2) | CN100513570C (tr) |
| AR (2) | AR024391A1 (tr) |
| AT (1) | ATE422545T1 (tr) |
| AU (3) | AU777461B2 (tr) |
| BR (2) | BR0011753A (tr) |
| CA (2) | CA2375787C (tr) |
| DE (1) | DE60041545D1 (tr) |
| HK (2) | HK1046427A1 (tr) |
| IL (2) | IL147022A0 (tr) |
| MX (2) | MXPA01013175A (tr) |
| NO (2) | NO20016121L (tr) |
| NZ (3) | NZ531401A (tr) |
| SG (2) | SG121853A1 (tr) |
| TR (2) | TR200200441T2 (tr) |
| TW (2) | TWI259205B (tr) |
| WO (2) | WO2000078971A2 (tr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60035163T2 (de) | 1999-03-15 | 2008-02-21 | University Of British Columbia, Vancouver | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| CA2382562A1 (en) * | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| MXPA02010684A (es) | 2000-05-02 | 2003-03-10 | Aventis Pharma Sa | Secuencias de acido nucleico regulador del gen abc1. |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
| CA2463395A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Therapeutic agents for low hdl-cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| ES2367539T3 (es) | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| US8466143B2 (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US8119686B2 (en) | 2006-11-24 | 2012-02-21 | Hykes Laboratories Llc | Spiroquinone compound and pharmaceutical composition |
| CA2673331A1 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| GB2470328A (en) | 2008-03-05 | 2010-11-17 | Ablynx Nv | Novel antigen binding dimer complexes, methods of making and uses thereof |
| JP2011516520A (ja) | 2008-04-07 | 2011-05-26 | アブリンクス エン．ヴェー． | Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用 |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| EP2414521B1 (en) * | 2009-03-31 | 2016-10-26 | The General Hospital Corporation | Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders |
| NZ595461A (en) | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| AU2011328246B2 (en) | 2010-11-08 | 2016-06-30 | Ablynx N.V. | CXCR2 binding polypeptides |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| EP2723772A1 (en) | 2011-06-23 | 2014-04-30 | Ablynx N.V. | Immunoglobulin single variable domains directed against ige |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| CN105209039B (zh) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| KR20180080337A (ko) | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| BR112019010061A2 (pt) | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
| TW202417517A (zh) | 2017-06-02 | 2024-05-01 | 德商麥克專利有限公司 | 與ｍｍｐ１３結合之免疫球蛋白 |
| CN118894939A (zh) | 2017-06-02 | 2024-11-05 | 默克专利股份有限公司 | 结合adamts的免疫球蛋白 |
| NZ759601A (en) | 2017-06-02 | 2023-06-30 | Merck Patent Gmbh | Aggrecan binding immunoglobulins |
| JP7249961B2 (ja) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド |
| IL296251A (en) * | 2020-03-06 | 2022-11-01 | Endolytix Tech Inc | Compositions and methods for the treatment of intracellular bacterial infections |
| CN115433733B (zh) | 2021-06-04 | 2025-12-12 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| CA3262070A1 (en) | 2022-07-14 | 2025-06-13 | Bio-Thera Solutions, Ltd. | ANTI-NECTIN-4 ANTIBODIES AND THEIR USES |
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| EP4731770A1 (en) | 2023-06-22 | 2026-04-29 | Ablynx NV | Chimeric proteins for modulating cytokine receptor activity |
| CN118027196B (zh) | 2023-06-25 | 2025-12-02 | 合肥天港免疫药物有限公司 | 抗cd3抗体及其应用 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| CN119569886A (zh) | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2025056575A1 (en) | 2023-09-11 | 2025-03-20 | Novo Nordisk A/S | Anti il-6 domain antibodies |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| TW202543670A (zh) | 2023-12-22 | 2025-11-16 | 比利時商艾伯霖克斯公司 | 用於核內投予之基於蛋白質的接合載劑 |
| TW202542180A (zh) | 2023-12-22 | 2025-11-01 | 比利時商艾伯霖克斯公司 | 用於位點特異性胺軛合的基於蛋白質的載體 |
| WO2025207946A1 (en) | 2024-03-28 | 2025-10-02 | Genzyme Corporation | Polypeptides binding to a specific epitope of the transferrin receptor 1 |
| US20260007757A1 (en) | 2024-06-18 | 2026-01-08 | Ablynx Nv | Antibody-recruiting molecules |
| WO2026078159A1 (en) | 2024-10-10 | 2026-04-16 | Ablynx Nv | Immune cell engagers and methods comprising the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02010684A (es) * | 2000-05-02 | 2003-03-10 | Aventis Pharma Sa | Secuencias de acido nucleico regulador del gen abc1. |
-
2000
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Ceased
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active Expired - Fee Related
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/tr unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/tr unknown
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Ceased
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/zh unknown
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Ceased
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
-
2001
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200440T2 (tr) | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler | |
| ATE147512T1 (de) | Sequenz-spezifische dns-bindung durch p53 | |
| DK1005488T3 (da) | Receptor som binder TRAIL | |
| Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
| NL300137I1 (nl) | Recombinante proteïnen van virussen geassocieerd met het | |
| ATE378407T1 (de) | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen | |
| Huse et al. | Semisynthesis of hyperphosphorylated type I TGFβ receptor: addressing the mechanism of kinase activation | |
| WO2003065003A3 (en) | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof | |
| Moeremans et al. | FerriDye: colloidal iron binding followed by Perls' reaction for the staining of proteins transferred from sodium dodecyl sulfate gels to nitrocellulose and positively charged nylon membranes | |
| AU3217100A (en) | Methods of use of a novel lysyl oxidase-related protein | |
| TR200000331T2 (tr) | Yeni yaşlanma faktörü geni P23'ün izolasyonu. | |
| AU3618095A (en) | Alk-7 (activin like kinase), a serine threonine kinase receptor | |
| ATE424456T1 (de) | Säugetier-rezeptorproteine; ähnliche reagentien und methoden | |
| SE9801148D0 (sv) | New receptors | |
| WO2003088910A3 (en) | Methods of assaying for cell cycle modulators | |
| WO2003008626A3 (en) | Novel human nucleic acids encoding a pantothenate kinase and methods of use | |
| DE69735604D1 (de) | Hypophysentumor verursachende gene und verwandte produkte | |
| Woodfin et al. | Spectrophotometric determination of the dissociation constant of ribonuclease S' | |
| ATE308615T1 (de) | T-bet zusammensetzungen und deren vervendungsmethoden | |
| Iida et al. | Identification of novel fibronectin fragments detected specifically in juvenile urine | |
| EA200300420A1 (ru) | Выделенная молекула нуклеиновой кислоты, выделенный полипептид и способ его получения, способ обнаружения их присутствия в образце (варианты), клетка-хозяин (варианты), антитело, набор (варианты), способ модулирования активности полипептида, способ идентификации (варианты) и применение соединения, способ выявления субъекта (варианты) и способ лечения субъекта с нарушением, связанным с калиевыми каналами (варианты) | |
| Chataway et al. | Studies on the iodination of a ras protein and the detection of ras polymers | |
| WO2002004601A3 (en) | Mammalian mdm2 binding proteins and uses thereof | |
| JP2005513054A5 (tr) | ||
| ATE382059T1 (de) | Neue humane androgenrezeptor-varianten |